Sample
Serum, plasma, bronchoalveolar lavage fluid (BALF)
Intended Use
Enzyme Immunoassay for the quantitative determination of KL-6 in human serum, plasma and bronchoalveolar lavage fluid (BALF).
Contents of Kit
1. Antibody Coated Microtiter Plate, 96 wells
2. Biotin-labelled Antibody, 13 mL
3. Streptavidin-HRP Conjugate, 13 mL
4. Master Standard, 1 vial
5. Quality Control A (human serum, lyophilized), 1 vial
6. Quality Control B (human serum, lyophilized), 1 vial
7. Dilution Buffer, 2×13 mL
8. Wash Buffer 15× conc., 50 mL
9. Substrate Solution, 13 mL
10. STOP Solution, 13 mL
Storage
The kit must be stored at 2 – 8°C.
The opened components can be stored for one week at 2 – 8°C.
Precision
1. Intra-assay
2. Inter-assay (Run – to – run)
Sensitivity
The limit of detection, defined as a concentration of human KL-6 giving absorbance higher than absorbance of blank + 3 standard deviations, is better than 0.05 U/mL of sample.
General Description
Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a 200 kDa glycoprotein that is predominantly expressed by damaged alveolar type II cells, and it has been proposed as a potential biomarker of different ILD.
KL-6 has profibrotic and anti-apoptotic effects on lung fibroblasts and reflects the degree and severity of alveolar epithelial injury. KL-6 is predictive biomarker useful in the clinical management of ILD patients, particularly in patients with severe fibrotic lung disorders.
Serum KL-6 levels were also found elevated in Rheumatoid Arthritis – Associated IDL patients, and the levels positively correlated with HRCT fibrosis score.
Citations
Publication ()
Have you cited DEIA4713 in a publication?
Let us know and earn a reward for your research.
COA
Loading ......
